New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
The tumor necrosis factor-а inhibitor etanercept (ETC) is one of the most popular members of the group of biologic disease-modifying antirheumatic drugs used for treatment of immune-mediated inflammatory rheumatic diseases (IRD). According to a series of double-blind randomized controlled trials (RC...
Main Authors: | A. E. Karateev, A. M. Lila |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2022-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1377 |
Similar Items
-
EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
by: O. Yu. Konopel'ko, et al.
Published: (2013-12-01) -
Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01) -
Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01) -
Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01) -
Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)